… INSERM TRANSFERT, YOUR
PARTNER FOR VALUE CREATION
AND TECHNOLOGY TRANSFER
Inserm Transfert, specialised in technology transfer and life sciences, was founded in 2000.
It is the private subsidiary of Inserm under a Public Service Delegation agreement. The company supports Inserm research units and researchers in the process undertaken to create value from their work. Its actions are part of the translational continuum, from basic and technological to clinical research, and are used for the creation of economic and societal value.
... NEWS PRESS
Inserm Transfert se félicite du Prix de l’inventeur européen décerné à Jérôme Galon par l’Office Européen des BrevetsAvec plus d’une cinquantaine de brevets et une marque, la réussite de l’Immunoscore® ; un test pour améliorer la prise […]
Therachon : un bel exemple de succès collectif pour une start-up, créée grâce à l’écosystème construit par l’Inserm, Inserm Transfert et Inserm Transfert InitiativeLe laboratoire Pfizer a annoncé le 8 mai dernier le rachat de Therachon à ses actionnaires, dont Inserm Transfert Initiative, […]
Human Health Startup Factory (HHSF) le consortium porté par Inserm Transfert, CNRS Innovation, la SATT IDF Innov et Deeptech Founders est labellisé aujourd’hui par BPIFranceCe consortium nouvellement labellisé a pour objectif d’accompagner les projets de création d’entreprise en santé humaine grâce aux compétences et […]
The EE-ASI project is an innovative ASI approach which combines technologies brought by academic partnerships and two SMES.
The EBOVAC2 project is intended to assess the safety and efficacy of a new preventative vaccine regimen against EVD.
The overall objective of this project is to develop and provide rapid, ambulatory diagnostic tools which will considerably increase our […]
CARMMA is based on the new hypothesis that the comorbidities of obesity are related premature senescence of adipose tissue (AT).
A European group of university laboratories and scientists working for industrial SME companies, combining integrated systems biology and comparative genomics […]
The aim of EHVA is to develop several innovative concepts in vaccines against HIV, both for prophylaxis and treatment.
This project will help to construct and assess a stratified health promotion programme based on so-called “omics” technologies for patients […]
ERINHA is a research infrastructure intended to improve European preparation and response, in terms of research, to combat highly […]
The aim of GENEGRAFT is to conduct a phase I/II clinical study on ex vivo gene therapy in 3 patients […]
The European programme – “Research into neurodegenerative diseases” (JPND) is the largest worldwide research initiative intended to respond to the […]
The primary objectives of MEDIT-AGEING are to improve early detection of Alzheimer’s disease and the understanding of its pathophysiological mechanisms […]
METACARDIS is developing an approach to systemic medicine at several levels in order to identify biological relationship between the intestinal […]
IMMUNOSCORE® measures the density of two T lymphocyte populations – CD8 and CD3 – which are found within and at […]
INSERM TRANSFERT has developed unique expertise in the development and negotiation of public/private partnerships (PPP) linked to research projects involving […]
Since 2011, MedImmune, the AstraZeneca international biological substances unit, has contributed to the advancement of Inserm laboratory research in several […]
The Team run by Didier Letourneur, CNRS Research Director and Director of Inserm U1148, located in Paris and awarded the […]